Ignite Creation Date:
2024-05-06 @ 3:36 PM
Last Modification Date:
2024-10-26 @ 1:53 PM
Study NCT ID:
NCT04696055
Status:
COMPLETED
Last Update Posted:
2024-05-01
First Post:
2021-01-04
Brief Title:
Regorafenib Plus Pembrolizumab in Patients With Advanced or Spreading Liver Cancer Who Have Been Previously Treated With PD-1PD-L1 Immune Checkpoint Inhibitors
Sponsor:
Bayer
Organization:
Bayer
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-02-03
Start Date Type:
ACTUAL
Primary Completion Date:
2022-05-05
Primary Completion Date Type:
ACTUAL
Completion Date:
2024-04-23
Completion Date Type:
ACTUAL
First Submit Date:
2021-01-04
First Submit QC Date:
January 4 2021
Study First Post Date:
2021-01-06
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
2023-05-30
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-04-29
Last Update Post Date:
2024-05-01
Last Update Post Date Type:
ACTUAL